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Cerebral malaria is the most severe and rapidly fatal neurological complication of Plasmo-
dium  falciparum infection and responsible for more than two million deaths annually. The
current therapy is inadequate in terms of reducing mortality or post-treatment symptoms
such  as neurological and cognitive deﬁcits. The pathophysiology of cerebral malaria is quite
complex and offers a variety of targets which remain to be exploited for better therapeutic
outcome.  The present review discusses on the pathophysiology of cerebral malaria with par-erebral malaria
urcumin
djunctive
ognitive deﬁcit
ticular emphasis on scope and promises of curcumin as an adjunctive therapy to improve
survival  and overcome neurological deﬁcits.
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arasitic diseases have grown to become a health burden as
round 30% of the world’s population experience parasitic
nfections.1 Among various parasitic infections, malaria is the
ost  life-threatening disease and accounts for 225 million
linical  cases and 781,000 deaths per year worldwide of which
1%  are in the African region. Beside this background, it is
eported  that each year about 85% of deaths globally are in
hildren  under ﬁve years of age, mainly due to the immunolog-
cal  factors.2 A total of US$ 38–45 billion will be spent from 2006
o  2015 for the diagnosis and treatment of malaria, mainly
n  underdeveloped countries which are the most affected by
his  deadly disease.3 Cerebral malaria (CM) is the most severe
nd  rapidly fatal neurological complication of Plasmodium fal-
iparum  infection and responsible for more  than two million
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Este é um artigo Open Access sob a licençadeaths annually in non-immune individuals characterized
by  impaired consciousness.4 This represents an enormous
burden of disease, due to the high prevalence of infection.
According to the World Health Organization (WHO), CM is
deﬁned  as a clinical syndrome characterized by coma (inabil-
ity  to localize a painful stimulus) at least 1 h after termination
of  a seizure or correction of hypoglycaemia, presence of asex-
ual  forms of P. falciparum malaria parasites on peripheral blood
smears  and exclusion of other causes of encephalopathy.5
Till now, no effective vaccine is available against malaria
because of the antigenic variation and complexity of parasite
biology.  The current therapy for management of CM is based
on  parenteral administration of either quinine or artemisinin@gmail.com (K. Gowthamarajan).
derivatives such as artemether and artesunate. However, the
emergence  of drug resistance of P. falciparum to anti-malarials
poses  a serious challenge to malaria control. In addition,
there are several non-parasitic events that contribute to
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monitored every 4 h. Fluid requirement should be assessed580  b r a z j i n f e c t d 
pathogenesis of CM.  The current therapy is aimed at reducing
parasite  burden and is inadequate in terms of reducing mor-
tality  or post-treatment symptoms such as neurological and
cognitive  deﬁcits. These facts necessitate novel interventions
for  better therapeutic outcome in CM.  Therefore, there is
an  urgent need to develop new antimalarial drugs, drug
combinations or alternative strategies for the management
of  CM.  The present review discusses on the pathophysiology
of CM with particular emphasis on the use of curcumin, a
natural  polyphenol, as an adjunctive therapy.
Clinical  manifestations  of  cerebral  malaria
The clinical hallmark of CM is impaired consciousness with
coma,  generalized convulsions and neurological sequelae as
the most severe manifestations. The earliest manifestations
are  non-speciﬁc fever, rigours and/or chills, irritability, rest-
lessness  or psychotic behaviour, vomiting and cough. The
main  symptoms in children are severe anemia, metabolic
acidosis, hypoglycemia and coma initially arousable which
becomes  unarousable later. These clinical features are most
strongly  associated with an increased risk of death in
children  admitted to hospital with severe malaria. Gastroin-
testinal  symptoms are common in children. In adults CM,
renal  failure, severe jaundice, and adult respiratory dis-
tress  syndrome are the main complications. Ten percent of
the  adult patients develop severe intravascular hemolysis
of  infected and uninfected RBCs leading to hemoglobin-
uria and anemia which further contributes to renal failure.
Pregnant women  are also vulnerable and develop anemia,
hypoglycemia, coma and pulmonary edema. Shock is not a
common feature of severe malaria and if present may  be due
to  septicemia.6,7
In children, coma develops suddenly followed by seizures
in  80% of the cases following 1–3 days of fever but some-
times just after few hours. In contrast in adults, coma develops
gradually  and is occasionally associated with seizures. Clinical
seizures  are associated with rise in intracranial pressure. Sta-
tus epilepticus is common in children and rare in adults. These
patients  often have deviated eyes, irregular breathing pattern,
and  show excessive salivation. On neurological examination,
Table 1 – Treatment of cerebral malaria.
Drug Route Indicated for Load
Quinine dihydrochloride IV Children and adults 20 mg/kg ove
600 mg)
Quinine dihydrochloride IV Children 15–20 mg/kg
Quinine dihydrochloride IM Children and adults 20 mg/kg (di
formulation
given in two
(anterior  thi
Quinidine gluconate IV Children and adults 10 mg/kg in 
over 1–2 h
Artemether IM Children and adults 3.2 mg/kg 
Artesunate IM/IV Children and adults 2.4 mg/kg 
Reproduced with permission from Ref.9. 1 3;1  7(5):579–591
signs of meningism are uncommon but neck stiffness can be
seen occasionally.8
Brain swelling, high intracranial pressure, changes in ocu-
lar  movements, retinal changes (hemorrhages, peripheral and
macular  whitening, vessel discoloration and/or papilledema)
and  brainstem signs (abnormalities in posture, pupil size and
reaction,  ocular movements or abnormal respiratory patterns)
are  commonly observed. Various forms of abnormal posturing
can  occur in association with hypoglycemia. It can be either of
decorticate  or decerebrate pattern and often indicates raised
intracranial  pressure. Bruxism with grinding of teeth, pout
reﬂex  or brisk jaw jerk is common in cases with deep coma.
Cranial  nerve involvement is sometimes observed in adults
but  is rare in children.8,9
Clinical  management  of  cerebral  malaria
Management of severe malaria comprises of four main areas:
clinical  assessment of patient, speciﬁc antimalarial treatment,
adjunctive therapy, and supportive care.
An open airway must be maintained in unconscious
patients and breathing and circulation should be assessed.
The  patients should be weighed so that treatment can be
done  accordingly. Blood glucose, hematocrit/hemoglobin, par-
asitemia and renal functions must be assessed. The coma can
be assessed using Glasgow scale in adults and Blantyre scale
in  children. Cerebrospinal ﬂuid analysis shall be carried out
to  exclude bacterial meningitis as it may  co-exist in endemic
areas.  Speciﬁc antimalarial treatment is described in Table 1.
In  attempt to reduce high mortality rate in severe malaria
various adjunctive treatments have been suggested and are
summarized  in Table 2.
Patients with severe malaria require intensive nursing
care.  Clinical observations such as coma and other vital
signs  should be monitored regularly. Blood glucose should beindividually. Patients with intravascular coagulation should be
given fresh whole blood transfusion and vitamin K. Any con-
comitant  infections should be treated with antibiotics based
on  culture and sensitivity results.
ing dose Maintenance dose
r 2–4 h (max 10  mg/kg every 8 h, until able to take orally
 over 2–4 h 10 mg/kg every 12 h, until able to take orally
lute iv
 to 60 mg/mL)
 injection sites
gh)
10  mg/kg every 8–12 h until able to take orally
normal saline 0.02  mg/kg/min continuous infusion with ECG
monitoring up to 72 h or 10 mg/kg every 8–12 h
1.6 mg/kg/day for a minimum of 5 days
1.2 mg/kg after 12 and 24 h, then 1.2 mg/kg/day
for 7 days; change to oral route when possible
b r a z j i n f e c t d i s . 2 0 1 3;1 7(5):579–591  581
Table 2 – Clinical management of severe manifestations and complications of P. falciparum malaria.5
Complication Management
Coma (cerebral malaria) Maintain airway, place patient on his or her side, exclude other treatable causes of coma
(hypoglycemia, bacterial meningitis), avoid harmful ancillary treatment such as corticosteroids,
heparin  and adrenaline
Convulsions Maintain airways; treat with intravenous or rectal diazepam
Hypoglycemia Measure blood glucose and maintain glucose level with infusion
Anemia Transfuse with screened fresh whole blood
Hyperpyrexia Use tepid sponging, fanning and antipyretic drugs. Paracetamol is preferred over other NSAIDs
Acute pulmonary edema Patient should be laid at an angle of 45◦, give oxygen and diuretics; prevent excessive rehydration
and stop iv ﬂuids
Acute renal failure Exclude dehydration; check ﬂuid balance and urinary sodium; hemoﬁlteration or hemodialysis to
be carried out if necessary (e.g. in renal failure)
Bleeding and intravascular coagulation Transfuse with fresh screened whole blood, give vitamin K
Metabolic acidosis Exclude or treat hypoglycemia, hypovolemia and gram negative septicaemia
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athophysiology  of  cerebral  malaria
alaria is a protozoal disease of humans and its neurological
omplication, CM is a multisystem multi-organ dysfunction
hich  is arguably one of the most common non-traumatic
ncephalopathies in the world.10 The pathogenesis of CM is
till  not fully understood because the animal models do not
ecapitulate  human disease completely. Thereby, in vivo and
n  vitro models are useful for hypothesis generation but proof
f  causation in clinical pathogenesis, naturally, must be inves-
igated  in human patients. The combination of both parasite
nd  host factors is involved in the pathogenesis of CM.
The  pathogenesis of CM results from the adherence and
equestration of parasitized red blood cells (PRBCs), immune
ells  and platelets to vascular endothelial cells (ECs) lining the
mall  blood vessels of the brain leading to their blockade.11
his is further accompanied by over production of type-
 pro-inﬂammatory cytokines followed by upregulation of
ndothelial  adhesion molecules (Fig. 1).12 It leads to micro-
nd  ring-hemorrhages and necrosis of the surrounding tis-
ues  and brain edema resulting in a signiﬁcant compression
f  cerebral arteries that could ultimately represent the cause of
eath.13 The symptoms of CM range from confusion or stupor
o  obtundation, convulsions and deep coma with long-term
eurological deﬁcits such as cortical blindness.14
ytoadherence
ytoadherence is deﬁned as adherence of PRBCs to the vascu-
ar  endothelium, mediated by Plasmodium derived proteins on
he surface of PRBCs and modiﬁed erythrocyte cell wall pro-
eins  and ligands on the ECs.15 The best described adhesin
rotein is parasite protein PfEMP-1 (P. falciparum erythrocyte
embrane protein-1) which is a large transmembrane protein
200–350  kDa) comprising several external Duffy-binding-like
DBL) domains. It is encoded by a family of more  than 150
16ighly  variable (“var”) genes. These are knob-like electron
ense  structures protruding from the PRBCs surface. The role
f  the knobs in cytoadherence was  conﬁrmed when knob-
ess  variant of P. falciparum were shown to lack adherenced for cultures, give parenteral antimicrobials, correct
to  host cells in vitro as well as in vivo.17 Surface poten-
tial spectroscopy studies of knobs revealed that they were
positively  charged and hence better electrostatic interaction
with  negatively charged endothelial plasma membranes and
receptors.18 These high molecular (200–350 kDa) transmem-
brane proteins are encoded PfEMP-1 mediated cytoadhesion
begins at approximately 12 h of parasite development and is
highly effective in the second half of P. falciparum life cycle.
As  a result, late stage of parasite (trophozoites and schizonts)
is  rarely seen in peripheral blood because of their seques-
tration in various organs.19 The large number of variants
of  PfEMP-1 results in potential of infected RBCs to bind to
many  different host receptors expressed on vascular ECs in
peripheral  microvascular beds.20 There are several cell adhe-
sion  receptors that have been characterized including ICAM-1
(intercellular adhesion molecule-1), VCAM-1 (vascular cell
adhesion  molecule), CD36, CD31, thrombospondin, E-selectin,
hyaluronic acid and chondroitin sulfate A (CSA).8 Cytoadher-
ence  prevents malarial parasites from being recognized and
cleared  off the circulation by the spleen.21
CD36 seems to be constitutionally expressed on wide range
of  vascular beds but remarkably absent in brain vessels and
thus  its expression is not related qualitatively or quantitatively
to  disease severity.22 This receptor is present in the microvas-
culature and its expression is not affected by inﬂammatory
cytokines like tumour necrosis factor- (TNF-).23 However,
platelets expressing CD36 may  serve as a stick bridge between
PRBCs  and endothelium which could be important in cerebral
vessels  lacking CD36 CSA is the main receptor in the placenta
which  in addition to CD36, are able to support ﬁrm adhesion
under  ﬂow conditions.24 The E-selectin mediates initial tether-
ing  to the ECs and rolling of leukocytes. Plasma concentration
of  soluble E-selectin is raised in P. falciparum malaria.25
Main receptor for the cytoadherence is ICAM-1, which has
been  implicated in the pathogenesis of CM.  It is a mem-
brane  glycoprotein expressed on lymphocytes, macrophages
and  vascular endothelium. Its primary role is to mediate
cellular adhesion within the immune system via the leu-
26cocyte  integrins LFA-1 and MAC-1. Expression of ICAM-1
on  human vascular endothelium can be upregulated by the
pro-inﬂammatory cytokines, TNF-, Interferon- (IFN-) and
Interleukin 1- (IL 1-).27 Regulation of ICAM-1 was shown to
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Fig. 1 – The blood–brain barrier (BBB) breakdown during cerebral malaria pathogenesis. The diagram shows the events and
the possible mechanisms that play a vital role in CM.  The mature forms (trophozoites and schizonts) of parasitized red
blood cells (PRBCs), host leukocytes and platelet-ﬁbrin thrombi adhere to the cerebral endothelial cells and sequester in
large numbers in the brain. This cytoadherence, combined with other events such as rosetting, auto-agglutination,
clumping  and decreased RBCs and PRBCs deformability causes altered blood ﬂow leading to impaired tissue perfusion and
hypoxia. Further, sequestered parasites produce local toxins which lead to recruitment of leukocytes and platelets followed
by the release of inﬂammatory cytokines (IL-1, IL-6, TNF, LT, and NO) and microparticles. These mediators lead to
endothelial cells activation and apoptosis, BBB breakdown, increased junctional permeability, followed by secondary
neuropathological events that can lead to cerebral edema or coma. Sequestration of PRBCs within microvasculature
increases cerebral volume, which together with increased cerebral blood ﬂow from seizures, anemia and hyperthermia and
altered BBB function lead to cerebral edema and raised intracranial pressure. This may  result in death or neuronal damage
with consequent neurocognitive sequelae in the survivors.
involve the endothelial nuclear factor kappa beta (NFB) sys-
tem  and may  involve reactive oxygen species (ROS).28 NFB is a
transcription factor located within cytoplasm and responsible
for  regulation of cytokine production. Normally NFB stays
inactivated by an inhibitory protein IB. Once activated, NFB
enters the nucleus and increases the transcription of different
inﬂammatory mediators such as cytokines and chemokines
(TNF-,  IL, etc.) thereby causing neuroinﬂammation. Several
molecules are capable of activating NFB including TNF-29
Monoclonal antibodies have been developed against ICAM-1
to  improve microcirculatory ﬂow in ex vivo models of malaria
sequestration but have not been investigated in humans.30
Recently, it has been reported that cytoadherence, a potential
pathogenic property of P. falciparum infected red blood cells,
continues  long after the parasite has been killed.31
SequestrationSequestration of PRBCs containing mature forms of the para-
site  (trophozoites and meronts) in the cerebral microvesselshas  been found on post-mortem examination of the CM
patients.32 The pathogenesis of fatal CM is associated with
sequestration of red blood cells. It has been conﬁrmed that
severe  malaria pathology is related to sequestered parasite
biomass.33 Sequestration occurs principally during the sec-
ond  half of the intra-erythrocytic asexual growth phase of
the  parasite, following the cytoadherence. The accumulation
of  mature PRBCs is observed in almost all organs, but par-
ticularly  in the brain viz. cerebrum, cerebellum and medulla
oblongata.11,32 This in turn, reduces the vascular lumen to cre-
ate  a mechanical obstruction for the erythrocytes transit. It is
the sequestered parasites that cause considerable obstruction
of  blood ﬂow, decreases tissue perfusion and removal of waste
products  like lactic acid and generates hypoxia.9,33
The relatively hypoxic venous beds provide optimal envi-
ronment  for the optimal growth and multiplication of
parasite  and prevents the PRBC from being destroyed by the
34spleen. Tissue hypoxia further causes hyperlactemia with
an  increased lactate pyruvate ratio and acidosis which are
the  strongest reproducible prognostic indicators in falciparum
malaria,  both in children and adults.35
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ed  cell  deformability,  rosetting  and
uto-agglutination
arasitized erythrocytes and non-parasitized erythrocytes
NPRBCs) sequestration in the cerebral microvasculature
educes the microvascular ﬂow. In addition, with progres-
ive  maturation of parasites inside erythrocytes decreases
heir  ability to deform which may  contribute to the eryth-
ocyte  destruction and impair the microcirculatory ﬂow.15
ecreased deformability of PRBCs is mainly due to change
n  the cytoskeleton, increased stiffness of the membrane
nd  rigidity of growing intracellular parasite. Such PRBCs
ave  more  difﬁculty in passing through in vitro micropore
lters as demonstrated for Plasmodium knowlesi malaria in
onkeys.36 Furthermore, it has been observed that NPRBCs
ave  to undergo considerable deformation as they squeeze
hrough  the sequestered microcirculation. It can be concluded
hat  deformability of both PRBCs and NPRBCs is markedly
educed in severe malaria which is partly contributing to the
athogenesis  of CM.37
The adherence of NPRBCs to PRBCs (rosetting) and PRBCs to
RBCs  (agglutination) could further compromise microcircula-
ory  ﬂow that leads to impaired tissue perfusion, hypoxia and
reates  a toxic local environment.15 This phenomenon is more
revalent  in patients with CM than in patients of uncompli-
ated  malaria. The var genes seem to be responsible for roset-
ing  and are sensitive to pH and heparin.38 Rosettes can be
isrupted  by antibodies against P. falciparum, glycosaminogly-
ans and sulfated glycoconjugates which is strain-speciﬁc.39,40
osette formation in vitro indicates the clogging of vascular
umen  by interaction of NPRBCs and PRBCs with endothelium.
owever, PRBCs causes the cytoadherence but not all form
osettes.41 Interestingly, epidemiological studies have shown
he  association of rosette forming strains with the develop-
ent  of severe disease but most clinical studies have failed to
how such an association.38,42 Red blood cells in thalassemic
nd sickle cell anemia patients have weak binding abilities
orming  small and weak rosettes. This decreased rosetting
bility  provides natural protection against development of CM
n such patients.43 Thus, it can be concluded that a com-
romised microcirculation, with sequestration of parasitized
rythrocytes due to reduced red cell deformability and the
ticky  forces related to rosetting and auto-agglutination, is
entral in the pathogenesis.
nﬂammatory  mediators
. falciparum infection causes an increase in blood concen-
ration  of both pro-inﬂammatory cytokines such as TNF-,
L-1,  IL-6, IL-18 and anti-inﬂammatory Th2 cytokines IL-4
nd  IL-10. The balance between these inﬂammatory medi-
tors  is critical to parasite control. However, their role in
athogenesis of disease remains unclear.44 Studies have
hown  that glycosylphosphatidylinositol (GPI), a malarial
oxin,  binds to the pattern recognition receptors of the innate
mmune  system and stimulates pro-inﬂammatory cytokine
roduction.45 GPI stimulates the production of TNF- and
ymphotoxin which further cause upregulation of expression3;1 7(5):579–591  583
of cytoadherence receptors notably ICAM-1 and VCAM-1
on  ECs. Thus, they promote sequestration of PRBCs and
leukocytes in brain leading to coma. The biological effects of
TNF-  during malaria are both protective and pathogenic.37,46
At low concentration, TNF- kills parasite by causing cytokine
release  from macrophages. Higher concentration of TNF-
is  associated with hypoglycemia, hyperparasitemia, anemia,
pulmonary edema and death.47
It has also been found that TNF activation leads to the
production of microparticles which have pro-coagulant and
pro-inﬂammatory properties and this is speciﬁcally seen in
patients  suffering from CM and does not occur in uncom-
plicated malaria or severe anemia.48 TNF- also induces the
release  of nitric oxide (NO) via inducible NO synthase (iNOS)
which  has been proposed as cause of coma due to interference
with  synaptic transmission.49
The effect of NO in malaria could be either beneﬁcial or
harmful  depending upon the amount and site of production.
Beneﬁcial effect of NO is involved in host defence by killing
intracellular organisms, maintaining vascular status and
neurotransmission.9 Although, the direct killing effect of NO
on  the parasite was  not observed, but oxidation products of
NO  were found to be toxic to the malarial parasite.50 Moreover,
it  was also shown that human monocytes stimulated with
IFN-  via the secretion of reactive nitrogen intermediates had
inhibitory  action on parasite growth in vitro.51 Measurement
of reactive nitrogen intermediates in various biological ﬂuids
such  as plasma, cerebrospinal ﬂuid and urine is very difﬁcult
since  NO is short lived, unstable and reacts rapidly with
several  molecular targets. This observation correlates poorly
with  in vivo production of NO at microvascular level. NO can
easily  diffuse across blood–brain barrier (BBB) and reduces the
level  of consciousness, impair neuronal signalling at higher
levels  and causes oxidative damage of ECs. Furthermore, NO
may  damage RBCs and increase anemia. To counteract the
damage  caused by the radical, NO scavengers might repre-
sent  an effective adjunct therapy. An alternative hypothesis
states  that NO production is limited and it is synthesized
by scavenging molecules such as superoxides and plasma
hemoglobin. Thus, enhancing NO bioavailability has been
proposed  as anti-malarial therapy.52 However, the role of
NO  in CM pathogenesis has not been elucidated clearly and
conﬂicting  observations have been reported.8
The cause of impaired consciousness is still unclear but it
is  likely to result from the in homogenous obstruction of the
cerebral  microcirculation by sequestered parasitized erythro-
cytes  causing dysoxia and results in lactate production by
the  brain.53 Apart from NO mediated loss of consciousness
various host and parasite derived factors may  be involved in
pathogenesis  of coma. Further, autopsy studies indicate the
axonal  dysfunction which may  arise due to accumulation of
-amyloid  precursor protein. This could in turn contribute to
the  reversible neurological dysfunction in CM.54 However, the
cause  of coma in CM and the role of dysoxia and axonal dys-
function  still remains unclear.Reactive  oxygen  species
Severe malaria patients are associated with an increased pro-
duction  of ROS by the phagocytic cells which in turn are
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Table 3 – Adjunctive therapy in cerebral malaria.
Failure Not proved Proposed
Aspirin Heparin Fasudil
Desferroxamine l-Arginine Atorvastatin
Dexamethasone Pentoxyfylline Curcumin
Immunoglobulins Levamisole
N-acetylcysteine Pf-EMP-1
Antagonists
Erythropoietinresponsible for the tissue damage. However, it was  suggested
that  ROS plays a role in host defense mechanism against the
parasite.55 Thus, likewise NO, ROS too can have both beneﬁcial
and  pathological roles.
Oxidative  stress (OS) plays a vital role in malaria parasite-
infected erythrocytes and at the same time OS represents
a  most promising rationale for designing the anti-malarial
chemotherapy. This has been indicated by the glucose-
6-phosphate dehydrogenase deﬁciency which makes the
malarial  parasites highly susceptible to alterations in the
redox  equilibrium. This in turn contributes to disease mani-
festation  including sequestration, cerebral pathology, anemia
and  respiratory distress.56 However, the redox interactions
between the malarial parasite and that of their host are
complex. Due to high metabolic rate of the rapidly growing
and  multiplying parasite, detoxiﬁcation of ROS becomes a
key  challenge for infected erythrocytes. Central to the gen-
eration  of toxic redox-active-by-products is the degradation
of  host hemoglobin by the Plasmodium. Hemoglobin repre-
sents  the major source of aminoacids for Plasmodium, but its
degradation  in an acidic food vacuole results in the produc-
tion  of toxic free heme (ferri/ferroprotoporphyrin IX; FP) and
ROS  which in turn confers oxidative insult on the host cell.
Hemozoin  or malaria pigment is a crystalline form of free
heme.  Even if only a small amount (e.g. 0.5%) of the free
heme  escapes the neutralization processes, it could cause OS
to host proteins and membranes, inhibit parasite enzymes
and  hemolysis.57 In addition, the production of ROS by the
host  immune system also contributes to the overall oxida-
tive  burden of the infected erythrocyte. In order to maintain
the  redox status, malarial parasite possesses an efﬁcient
enzymatic antioxidant defense system including glutathione-
and  thioredoxin-dependent proteins as well as superoxide
dismutase.56 In this regard, targeting the parasite antioxidant
defense system might be useful for designing antiparasitic
medication.
Indeed, a number of potential new drugs currently in
clinical  use, especially the artemisinins appear to act by
alkylation  of heme or protein to form a cytotoxic carbon-
centred radical intermediate that further interfere with the
redox  metabolism of malarial parasite.58 It seems likely that
the  lethal effects of endoperoxide antimalarial are due to
targeted  damage of particular enzymes or membrane pro-
teins  by free radical species rather than non-speciﬁc damage
caused  by freely diffusing ROS.59 Some antioxidants adjunc-
tive  therapy have been evaluated in humans and mice
(Table  3). 1 3;1  7(5):579–591
Increased  permeability  and  evidence  of
endothelial damage
The BBB is a highly specialized structural and functional inter-
face  between the intraerythrocytic stages of P. falciparum and
the  human host.60 BBB maintains functional integrity with
the  support of pericytes, microglial processes of neurons and
specialized  perivascular macrophages. Perivascular cells are
involved in maintaining the normal neuronal function of the
CNS  and provide immunity.61 There is growing evidence that
combination  of parasite-induced sequestration of PRBCs and
NPRBCs,  cytokine response, host environment, activation of
ECs  and hemostasis changes BBB function and its perme-
ability.  This has been implicated in the onset of a clinically
complex syndrome of coma with reversible encephalopathy,
associated with high mortality rate and increasingly recog-
nized  as long-term neurological sequelae in survivors.8,62
Pathological changes to BBB dysfunction may  be broadly
divided into systemic effects of severe disease such as acidosis
or  hypoxia due to anemia and local factors include adher-
ence  of PRBCs, host leukocytes and platelets to the ECs,
rosetting, sequestration, microvascular obstruction, release of
cytokines and parasite toxins. These cascade of events cause
direct  cellular damage and may  initiate signalling within
ECs  that could inﬂuence junctional protein expression, and
also  directly activate or damage peri- and paravascular cells
such  as microglia, astrocytes and neurons and parenchy-
mal  effector cells.14 It is believed that cerebral microvascular
engorged by cytoadherent parasitized erythrocytes results in
a cascade of intracellular signalling events that disrupts the
cytoskeleton-cell junction structure and increases the junc-
tional  permeability of the BBB and suppresses activation
of  dendritic cell and macrophages.12 Thus, dysfunction of
BBB  initiates the progression of secondary processes of neu-
ropathological injury.
Even  though P. falciparum disturbs the BBB integrity, it never
enters  the brain parenchyma and yet it can cause severe neu-
rological  dysfunction and death.14,61 Focal disruptions at sites
of  PRBCs sequestration along the ECs of BBB could result in the
exposure  of sensitive perivascular neuronal cells to plasma
proteins  and further leads to localized hypoxia and hemor-
rhaging  of surrounding brain parenchyma.12,14 Apart from
systemic effects, increased concentration of cytokines and
parasite  toxins have also been shown to contribute to reduced
consciousness and seizure activity. Thus causing direct dam-
age  to BBB.63
Studies have shown that PRBCs adhesion to ECs induces
cell  apoptosis via over expression of cytoadherent molecules,
expression of iNOS and OS.64 Further, in vivo studies in mice
model  of CM have implicated cytotoxic effector CD8+T lym-
phocytes  in development of murine CM pathogenesis by direct
cytotoxicity  against ECs.65 Thus, apoptosis and cytotoxicity
may  lead to disruption of BBB and endothelial damage.
In  patients, CM-associated brain damage can be studied
only  on post-mortem specimens and is the end-point of a
fatal  syndrome. Post-mortem analysis of infected brain tis-
sue  from severe P. falciparum cases has shown ECs activation,
vascular congestion, varying degree of cerebral edema, leak-
age  of plasma into brain interstitium, upregulation of ICAM-1,
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etechial hemorrhage particularly of white matter and ring
emorrhages in white matter.9,15
The leakage of plasma into CSF and consequent elevation
f  its protein concentration due to breakdown of BBB has
een  demonstrated by parenteral administration of radioac-
ive  albumin and isothioacyanite in animal models.66
BBB disruption can contribute to severe increased intracra-
ial  hypertension which is associated with neurological
equelae or death. However, the most likely cause of raised
ntracranial hypertension includes increased cerebral blood
olume  due to sequestration and increased blood ﬂow from
eizures,  hyperthermia and anemia. Mannitol is an effec-
ive  osmotic diuretic in reducing the burden of brain edema
nd  intracranial pressure in children with mild degree of
ntracranial  hypertension. It may  decrease the mortality or
eurological deﬁcits in surviving patients of CM.67
eurocognitive  deﬁcits
hough most of the patients suffering from CM make a full
ecovery,  survivors have been found to be associated with
eurological sequelae.9 CM sequelae seem to be of multi-
actorial origin, although their cause is largely unknown.
hese impairments are rarely observed in adults (<1%) but
re  more  common in children (approx ∼ 12%) particularly
n sub-Saharan Africa.68 The symptoms include hemiplegia
r  quadriparesis, cortical blindness, deafness, ataxia, severe
ypotension and aphasia.69 The sequelae reported include
rotracted seizures, prolonged and deep coma, hypoglycemia
nd  sometimes severe anemia.9 Some of these symptoms
esolve over a period of 1–6 months in 50% of the children.
owever, 25% of children with successfully treated CM are
eft  with residual cognitive and neurological deﬁcits such as
emory  disturbances, speech and language difﬁculties, disor-
ers  of attention, seizures, visuo-spatial and motor deﬁcits.70
hese deﬁcits have been determined to persist after cessa-
ion  of therapy with follow-up periods extending to nine years
fter  infection.71 These cognitive deﬁcits occur as a result of
omplicated  host inﬂammatory response in conjunction with
ascular  impairment, causing abnormalities in neuronal cells,
hich adversely affect cognitive function.
Prolonged febrile seizures not precipitated by malaria
ay  lead to damage in the hippocampus associated
ith later episodic memory  impairments which may  be
nderreported.9,15,72 Further decreased in blood ﬂow and
elivery of oxygen may  lead to brain damage.15 The other
easons include generation of excitotoxins, ROS, and toxins
roduced  by the parasite.73
To date, there is no therapy targeting the cognitive and
otor  deﬁcits seen after successful antimalarial therapy in
xperimental  CM.  Hence, the role of immunomodulator needs
o  be assessed as an adjunctive therapy in CM.
evere  Plasmodium  vivax  infections  and
eurological complications. vivax infections considered as a benign disease for a long
ime  is the major cause of morbidity in Asia, Central and
outh  America and in the horn of Africa.74 It is responsible3;1 7(5):579–591  585
for  more  than 400 million infections each year thus repre-
senting  most widespread malarial species.75 In 2010, 306,908
cases  of malaria were  recorded in Brazil, 85% of which were
caused  by P. vivax.76 P. vivax infections are characterized by
relapse  of malaria due to persistent latent forms in liver
called  as hypnozoites. In most of endemic areas, P. vivax infec-
tions  co-exist with P. falciparum infections. However, P. vivax
infections  are more  difﬁcult to control because of their ten-
dency  to relapse and is a major cause of malaria in young
children.74 Severe P. vivax infections are uncommon but have
been  reported at regular intervals. The number of vivax infec-
tions  particularly those with serious clinical complications
has been increasing. The most frequent complications are
severe  anemia, acute respiratory distress syndrome (ARDS),
thrombocytopenia, renal and hepatic dysfunction, coma, CM
and death.77 P. vivax infections have been rarely associated
with CM and to date less than 50 cases of central nervous
system P. vivax infections have been reported.78 Severe pul-
monary  involvement is frequent in P. falciparum infection but
rare in vivax malaria. Among the few cases reported involving
vivax,  the pulmonary complications appear from six to eight
days  after the initiation of antimalarial treatment. This is due
to  exacerbation of inﬂammatory response.79 However, in con-
trast  to P. falciparum associated respiratory distress, the lungs
are  the sole organ system involved in vivax malaria. It is asso-
ciated  with acute lung edema and neutrophil accumulation in
interalveolar space with or without sequestration of P. vivax
infected  RBCs.77,80
The mechanism of ARDS in vivax malaria is less well
studied compared to falciparum infections. The level of pro-
inﬂammatory mediators is elevated in vivax infections thus
signifying  the role of inﬂammatory dysregulation. There is a
cytokine related increase in alveolar permeability and altered
ﬂuid  clearance.81 In vivax infections, anemia persists even
after  the parasite clearance. The severe anemia in vivax infec-
tions  does not result from destruction of infected RBCs alone.
Studies  have shown that for every infected RBC destroyed in
vivax malaria, 32 uninfected RBCs are removed from circula-
tion  compared to eight RBCs in falciparum malaria.82
Immunopathogenesis of vivax malaria is poorly under-
stood. However, it was found that Brazilian patients with
severe  vivax malaria had elevated levels of inﬂammatory
cytokines TNF- and IFN-, increased IFN-/IL-10 ratio and
superoxide dismutase (SOD-I).83 The level of TNF- and other
inﬂammatory cytokines are higher during P. vivax infections
compared to P. falciparum infections with same parasite load.
Plasma  concentration of microparticles was  found to be ele-
vated  in individual with P. vivax infections.84 In contrast to
P.  falciparum, P. vivax has low parasite biomass and is con-
sidered  unable to cytoadhere or sequester. However, recently
P.  vivax infected RBCs have been shown to cytoadhere to
ECs  via chondroitin sulfate-A and ICAM-1 although at 10-fold
lesser  frequency than P. falciparum.85 This could be reason for
lower  incidence of coma in vivax malaria and coma is perhaps
of  systemic metabolic origin.86 The degree of endothelial acti-
vation  is greater in vivax than falciparum malaria. Rosetting in
P. vivax has not been well documented and has not been asso-
ciated  with disease severity. The difﬁculty of growing P. vivax
in  vitro and absence of speciﬁc and reliable biomarkers have
lead  to little knowledge about its pathogenesis and severe
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cases. In areas where both multidrug resistant P. falciparum
and  P. vivax are prevalent, infants and young children are at
greater  risk of acquiring P. vivax infection than P. falciparum
infection.87 Thus, an immunomodulator may  have a potential
role  in severe vivax infections.
Need  of  adjunctive  therapy  in  cerebral  malaria
Apart from P. falciparum induced cerebral injuries, CM is also
associated  with non-parasite events including OS and inﬂam-
matory  cascade which is responsible for mortality in spite of
antimalarial  treatment during the acute phase.88 CM is asso-
ciated  with elevated pro-inﬂammatory cytokines in serum
and  brain tissues, as well as leukocyte recruitment to sites
of  parasite sequestration in the cerebral microvasculature.
The harmful, deregulated immune response leading to CM is
mainly of the Th1 type, with overproduction of Interferon-
(IFN-) and TNF-.89 These inﬂammatory processes promote
pathological changes in the brain that contribute to CM,  such
as  endothelial damage and neuronal dysfunction. In spite
of  treatment with current antimalarials, CM is associated
with  mortality in 20–25% of cases and those surviving have
been  associated with neurological and cognitive deﬁcits.71 OS
has  been found as a contributing factor to persistent cog-
nitive  deﬁcits.90 ROS are generated in malaria as a result
of  host immune response and may  oxidize vital cellular
components such as lipids, proteins, and DNA. Oxidative
damage to membranes of parasitized and uninfected red
blood  cells may  contribute to sequestration of red blood cells
in  microvascular cells.91 The current therapy utilizing anti-
malarials  controls parasitic events alone and do not treat
the  inﬂammatory cascade. The control of these deleterious
processes is probably one of the most challenging goals to
reach  for a full rate recovery suggesting that adjunctive ther-
apies  are urgently needed with the aim of providing a new
therapeutic scheme for CM using a combination of a rapid
antimalarial and immunomodulators. Also, the reversal of
BBB  leakage or its downstream effects presents a potential
opportunity for neuroprotective therapy for patients with CM.
Apart from killing the parasite effectively, there is a need
to  improve survival rate and overcome cognitive deﬁcits in
CM  patients and therefore reduce the likelihood of perma-
nent  neurological disability or death. Thus, the objectives of
the  adjunctive therapy are mainly to decrease the mortal-
ity,  shorten the coma and reduce the rate and the severity
of  neurological sequelae. The ﬁrst adjunctive intervention
was  using anti-TNF antibody in the murine model and since
then  more  than 48 adjunctive interventions have been evalu-
ated  showing 92% success rate in ameliorating or preventing
CM.92 The adjunctive therapy may  involve the identiﬁcation
of  immune modifying compounds such as curcumin, with
ability  to downregulate excessive pro-inﬂammatory response,
reducing  the expression of the adhesion molecules and sub-
sequent  sequestration of PRBCs in cerebral endothelium, thus
improving the survival of CM patients. In contrast to many
adjunctive therapies which have been investigated, curcumin
has  an added advantage of possessing antimalarial efﬁcacy
of  its own. An important point to be considered for admin-
istration of adjunctive therapy using an immunomodulatoris that it should be administered together with antimalarial
drugs rather than alone in order to delay immunopathology
and allow a longer time frame for antimalarial to work.4 We  are
working  on intranasal delivery of curcumin loaded nanoemul-
sions  in combination with artemether for management of
CM.93
Curcumin  and  cerebral  malaria
Curcumin, a small molecular weight polyphenolic compound
isolated  from the rhizomes of Turmeric (Curcuma longa L.) and
related  species (family Zingiberaceae), has been used tradition-
ally  as a spice. The major curcuminoids present in turmeric
are  Curcumin (Curcumin I), Demethoxy curcumin (Curcumin
II)  and Bisdemethoxy curcumin (Curcumin III) (Fig. 2). Com-
mercial  curcumin contains curcumin I (77%), curcumin II (17%)
and  curcumin III (3%).94
Curcumin is from natural sources of long-term use, and as
such,  no resistance is known to curcumin that is present in
a  dietary supplement. It is tolerated at very high doses, and
as  much  as 8 g/day has been given for three months to cancer
patients  on trial without toxic side effects.95 A large number
of  in vitro and in vivo studies in both animals and humans
have  indicated that curcumin exhibits promising pharma-
cological activities including antioxidant, anti-inﬂammatory,
anti-angiogenic, anti-spasmodic, anti-microbial and anti-
plasmodial  activities. Accumulating evidence suggests that
curcumin  has a diverse range of molecular targets, suppor-
ting  the concept that it acts upon numerous biochemical and
molecular  cascades (Fig. 3).
In the context of malaria, curcumin has been shown to
possess  moderate antimalarial activity with IC50 value of
5–18  M.96,97 Further, curcumin analogues were  synthesized
having much  more  potent antimalarial activity with IC50 value
of  400 nM. With the use of the CM model in mice, it has been
shown  that curcumin have potent activity against Plasmo-
dium  berghei and it is able to prevent CM and delay death of
animals  by about 10 days.4,98 In addition to having a direct
killing effect as an antimalarial, curcumin is also able to
prime  the immune system against P. berghei.98 Curcumin pos-
sesses  both anti-oxidant and pro-oxidant activity. Curcumin
has  shown to enhance ROS generation in concentration range
of  20–100 M.99 The efﬁcacy of curcumin has been tested in
different  models of CM (Table 4).
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Fig. 3 – Molecular targets of curcumin in cerebral malaria.
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rargets  of  curcumin
urcumin has numerous molecular targets in the context of
M.  It possesses itself antimalarial activity and acts as a neu-
oprotective  agent:
i.  NF-B (nuclear factor  beta) plays a vital role in malaria
as  evidenced by PRBCs that have shown to induce NF-
B  regulated inﬂammatory pathway in human cerebral
endothelium. The deciphering of anti-malarial activity
in  curcumin against the blood phase of the life cycle
may  leads to its role in regulation of NF-B. Curcumin
has profound anti-inﬂammatory activity and might exert
its  therapeutic effects by pro-inﬂammatory cytokine pro-
duction  and expression of cytoadhesion molecules on
ECs.100 Curcumin has shown to reduce the production of
proinﬂammatory cytokines such as TNF, IL12 and IL6 in
vitro.101 It can be concluded that curcumin can effectively
control neuroinﬂammation and damage due to inﬂam-
matory cascade as a result of host immune response and
thereby  prevent cognitive deﬁcits in CM survivors.
ii. Curcumin activates PPAR- (peroxisome proliferator acti-
vated  receptor ). PPAR- is a transcription factor that
regulates inﬂammatory responses. Its activation inhibits
translocation of NF-B and inhibits microglia from pro-
ducing  proinﬂammatory cytokines.29 It also regulates
scavenger receptor CD36, which mediates non-opsonic
phagocytosis of PRBCs. Pharmacological upregulation of
CD36  in monocytes/macrophages by PPAR- agonists
has shown to increase CD36 dependent phagocytosis
of PRBCs in vitro.102 CD36 is also activated by acti-
vation of redox-sensitive transcription factor nuclear
related {erythroid-derived 2} factor (Nrf2). These two
transcription factors have been found to be activated
in  macrophages/monocytes treated with curcumin.103Activation of Nrf2 pathway has been demonstrated as
potential  target regarding brain inﬂammation.104
iii. It inhibits expression of various cell surface adhesion
molecules such as ICAM-1, VCAM-1 and endothelial
leukocyte adhesion molecule (ELAM-1) on ECs.94 These
data  support the development of adjunctive thera-
pies to reverse the pathophysiological consequences of
cytoadherence.31 Curcumin also inhibits adhesion of
platelets to brain ECs in vitro which accumulate in brain
blood  vessels in CM patients.105
iv. Curcumin causes inhibition of P. falciparum general con-
trol  nondepressed 5 (PfGCN5). It is a histone acetyl
transferase (HAT) that preferentially acetylates K9  and
K14  of histone H3. Various post-translational modi-
ﬁcations of histone tails lead to regulation of gene
expression. Curcumin inhibits HAT and causes parasite
chromatin modiﬁcations and have antiparasitic effects.99
v. Another target of curcumin is PfATP6 (P. falciparum
ATP6), the parasite analogue of SERCA (Sarcoplas-
mic/endoplasmic reticulum Ca2+ ATPase). PfATP6 is the
only  SERCA-type Ca2+ ATPase in P. falciparum which
is responsible for the maintenance of calcium ion
concentrations for the generation of calcium-mediated
signalling and correct folding and post-translational
processing of the proteins.106,107
vi. Curcumin inhibits iNOS by suppression of IFN- and IL-
12  production. iNOS has shown to mediate production of
ROS.108
vii. Heme oxygenase-1 (HO-1) is the rate limiting enzyme
involved in the breakdown of free toxic heme into car-
bon  monooxide, Fe and bilirubin. Curcumin upregulates
HO-1 gene and protein expression thereby protecting the
ECs  from peroxide mediated toxicity as well as toxicity
caused due to free heme. Bilirubin further inhibits the
ROS  production.109,110
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Table 4 – Curcumin examined for possible effects on animal models of malaria.
Mouse Treatment schedule Treatment effect Ref.
Dose Days p.i. Method
Albino mice (P. berghei ANKA) Curcuminoids
liposomes
10 mg/kg
20  mg/kg
40  mg/kg
0–3 IV For 10–20 mg/kg group, 60–70%
parasitemia on day 6, died by 7–8 days.
For  40 mg/kg group, suppressed
parasitemia up to 9 days and
prolonged  survival up to 11 days.
112
Swiss mice (P. berghei ANKA) Curcumin 100 mg/kg
for 5 days
0–2 Oral Curcumin treatment resulted in
overall survival rate of 29% compared
to  0% in vehicle fed animals 21 days
p.i.,  decreased blood parasitemia by
80–90%.
96
Swiss mice (P. yoelli) Curcumin loaded
chitosan
nanoparticles
33.33  mg/kg
3–10 Oral Curcumin bound chitosan
nanoparticles  prolonged survival up
to 15 days p.i. in comparison to day 9
of p.i. in control mice.
Curcumin  alone lead to survival of
33% mice whereas group treated with
curcumin nanoparticle showed 100%
survival.
113
Albino mice (P. berghei) Curcuminoid loaded
SLN,  NLC 100 mg/kg
–  IP Mice treated with drug loaded SLN
and  NLC showed signiﬁcantly 2 fold
longer survival as compared to control
and  free curcuminoids. All groups
showed  100% mortality at the end of
study.
114
ICR Harlam-Sprague Dawley and
C57BL/6  mice (P. berghei ANKA
MRA-311/GFP)
50  mg/kg twice a day 0–5 IP/Gavage IP injection of 25 mg/kg/d Curcumin
on day 1–9 p.i. was beneﬁcial in case
of  PbA GFP infection in ICR mice; no
effect was seen in case of PbA/ICR
infection.
Gavage  treatment of PbA infected
C57BL/6  prevented CM and delayed
death by 10 days, did not change
initial  parasitemia and no signiﬁcant
effect  was seen in ICR mice.
115viii. C-Jun N terminal kinases (JNK) belongs to the family of
mitogen  activated kinases called MAP  Kinases, which
are  activated in response to inﬂammatory cytokines and
environmental stress conditions. Its activation induces
the  transcription-dependent apoptotic signalling path-
way  resulting in neuronal cell death during experimental
CM.111 Curcumin suppresses JNK activation and thus pro-
tects  the neurons
ix.  Curcumin enhances the activity of detoxifying enzymes
like  Glutathione-S-transferase.29
All these mechanisms suggest curcumin as an
immunomodulator which may  alleviate CM.
ConclusionParadoxically the rate of new drug delivery in case of malaria
has  been very low. The global response to this crisis has been
inadequate.  There are few new chemical entities in preclinical
and  clinical phases but these efforts could take considerabletime to fructify. So far the attempts have been limited to
explore  the use of immunomodulator in combination with
conventional drugs for CM. Thus, this review highlights the
potential  of a plant based immunomodulator curcumin as an
adjunctive therapy for better management and improvement
of  survival and overcoming the neurocognitive deﬁcits in CM
patients.  It may  be a useful strategy to complement the direct
antiparasitic efﬁcacy of currently used antimalarials and also
limit the emergence of resistant parasites.
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